Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Non-Current Debt: 2022-2024

Historic Non-Current Debt for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $180.7 million.

  • Axsome Therapeutics' Non-Current Debt fell 34.64% to $117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.6 million, marking a year-over-year decrease of 34.64%. This contributed to the annual value of $180.7 million for FY2024, which is 1.48% up from last year.
  • Axsome Therapeutics' Non-Current Debt amounted to $180.7 million in FY2024, which was up 1.48% from $178.1 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Non-Current Debt ranged from a high of $180.7 million in FY2024 and a low of $94.3 million during FY2022.
  • Moreover, its 3-year median value for Non-Current Debt was $178.1 million (2023), whereas its average is $151.0 million.
  • Data for Axsome Therapeutics' Non-Current Debt shows a peak YoY surged of 88.92% (in 2023) over the last 5 years.
  • Over the past 3 years, Axsome Therapeutics' Non-Current Debt (Yearly) stood at $94.3 million in 2022, then spiked by 88.92% to $178.1 million in 2023, then rose by 1.48% to $180.7 million in 2024.